CSIMarket
 
Ibio inc   (IBIO)
Other Ticker:  
 
 
Price: $1.1500 $0.06 5.023%
Day's High: $1.15 Week Perf: 7.48 %
Day's Low: $ 1.08 30 Day Perf: -3.36 %
Volume (M): 547 52 Wk High: $ 49.00
Volume (M$): $ 629 52 Wk Avg: $8.75
Open: $1.12 52 Wk Low: $1.02



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -53
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 3

Ibio Inc
Ibio Inc. is a biotechnology company based in the United States. It primarily focuses on the development and commercialization of plant-based therapies and vaccines. Ibio utilizes a proprietary technology platform called FastPharming, which enables the rapid production of biologics using plants. The company collaborates with various partners to develop and manufacture therapeutic candidates for diseases such as cancer, fibrosis, and infectious diseases. Ibio also offers contract development and manufacturing services to other pharmaceutical and biotechnology companies.


   Company Address: 8800 HSC Parkway Bryan 77807 TX
   Company Phone Number: 446-0027   Stock Exchange / Ticker: NYSEAMER IBIO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Partnership

Augmenting Obesity and Cardiometabolic Disease Treatment: iBio and AstralBio's Transformative AI Collaboration

Published Wed, Mar 27 2024 11:00 AM UTC

The fight against obesity and cardiometabolic diseases continues to present significant challenges for the healthcare industry. However, a beacon of hope arises as two leading innovators, iBio and AstralBio, join forces in a transformative collaboration. Harnessing the power of Artificial Intelligence (AI) and precision biologics, this groundbreaking partnership aims to rapi...

Financing Agreement

iBio Secures $15 Million Private Placement with Significant Premium, Bolstering Growth Prospects

Published Tue, Mar 26 2024 11:35 PM UTC

iBio Announces Successful $15.0 Million Private Placement with Significant Premium to Last Close
iBio, a leading biologics contract manufacturing organization, has recently announced a successful private placement offering that raised $15.0 million. The purchase price of $2.85 per share represents a premium of over 148% to the last closing price, indicating strong invest...

Shares

iBio Executes 20-to-1 Reverse Stock Split to Propel Share Value and Market Presence

Published Mon, Nov 27 2023 10:20 PM UTC



iBio, Inc. (NYSEA:IBIO), a leading biotech company specialized in the development and manufacturing of biotherapeutics, has recently declared a 20-to-1 reverse stock split of its common stock. The decision, which received approval from the company's Board of Directors, aims to provide a much-needed boost to the firm's share value and improve overall market percepti...

Ibio Inc

Ibio Inc's Fourth Quarter Earnings Show Alarming Surge in Losses and Share Value Decline



In the aftermath of Ibio Inc's recently released fourth-quarter earnings report, the company appears to be grappling with mounting losses and a steep decline in its share value. The financial results for the quarter ended in 2023 revealed a concerning trend of escalating losses for the biotechnology firm.
Earnings Overview:
During the fourth quarter of the 2023 earnings season, Ibio Inc reported a significant increase in its loss per share compared to the same period in the prior year. The loss per share surged from $-0.10 a year ago to $-0.97, representing a substantial deterioration. Additionally, the company witnessed a sequential increase in losses, reaching $-0.55 per share from the previous financial reporting period.

Ibio Inc

Drastically Reduces Deficit and Boosts Income per Share in Recent Fiscal Period

The stock market has had its fair share of ups and downs lately, but some good news is on the horizon for investors. For the most recent fiscal period, company Diminishing Returns has seen an impressive improvement in its Income per Share, which has been reported as a positive sign for the company's future growth.
Not only has the Income per Share improved, but the company has also experienced a significant reduction in their net loss. Their net loss of $-7.294 million in the most recent fiscal period is a far cry from their deficit of $-11.920 million in the same quarter a year ago. These improvements show that Ibio Inc is on the right track and heading towards a more secure financial future.






 

Ibio Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com